Gene, Cell and Antibody-Based Therapies for the Treatment of Age-Related Macular Degeneration by Akyol E, Lotery A

Get full text

Requirement for retinal screening in patients taking hydroxychloroquine and chloroquine by Lotery, A, Yusuf, I

Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration by Chakravarthy, U, Harding, S, Rogers, C, Downes, S, Lotery, A, Wordsworth, S, Reeves, B

Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. by Chakravarthy, U, Harding, S, Rogers, C, Downes, S, Lotery, A, Wordsworth, S, Reeves, B

Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: One-year findings from the IVAN randomized trial by Chakravarthy, U, Harding, S, Rogers, C, Downes, S, Lotery, A, Wordsworth, S, Reeves, B

A retrospective study of the real-life utilization and effectiveness of ranibizumab therapy for neovascular age-related macular degeneration in the UK by Hykin P, Chakravarthy U, Lotery A, McKibbin M, Napier J, Sivaprasad S

Get full text

Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial by Chakravarthy, U, Harding, S, Rogers, C, Downes, S, Lotery, A, Culliford, L, Reeves, B

Pharmacogenetic Associations with Vascular Endothelial Growth Factor Inhibition in Participants with Neovascular Age-Related Macular Degeneration in the IVAN Study by Lotery, A, Cree, A, Gibson, J, Ennis, S, Downes, S, Harding, S, Rogers, C, Reeves, B, Chakravarthy, U

Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age-related macular degeneration in the ivan study by Lotery, A, Gibson, J, Cree, A, Downes, S, Harding, S, Rogers, C, Reeves, B, Ennis, S, Chakravarthy, U

Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial. by Dakin, H, Wordsworth, S, Rogers, C, Abangma, G, Raftery, J, Harding, S, Lotery, A, Downes, S, Chakravarthy, U, Reeves, B

Cohort profile: design and methods in the eye and vision consortium of UK Biobank by Chua, S, Thomas, D, Allen, N, Lotery, A, Desai, P, Patel, P, Muthy, Z, Sudlow, C, Peto, T, Khaw, P, Foster, P, Uk Biobank Eye & Vision Consortium

Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial. by Maclaren, R, Groppe, M, Barnard, A, Cottriall, C, Tolmachova, T, Seymour, L, Clark, K, During, M, Cremers, F, Black, G, Lotery, A, Downes, S, Webster, A, Seabra, M

Visual acuity after retinal gene therapy for Choroideremia by Edwards, T, Jolly, J, Groppe, M, Barnard, A, Cottriall, C, Tolmachova, T, Black, G, Webster, A, Lotery, A, Holder, G, Xue, K, Downes, S, Simunovic, M, Seabra, M, MacLaren, R

Missense mutations in a retinal pigment epithelium protein, bestrophin-1, cause retinitis pigmentosa. by Davidson, A, Millar, I, Urquhart, J, Burgess-Mullan, R, Shweikh, Y, Parry, N, O'Sullivan, J, Maher, G, McKibbin, M, Downes, S, Lotery, A, Jacobson, S, Brown, P, Black, G, Manson, F

Beneficial effects on vision in patients undergoing retinal gene therapy for choroideremia by Xue, K, Jolly, J, Barnard, A, Rudenko, A, Salvetti, A, Patrício, M, Edwards, T, Groppe, M, Orlans, H, Tolmachova, T, Black, G, Webster, A, Lotery, A, Holder, G, Downes, S, Seabra, M, MacLaren, R

Retinal gene therapy in patients with choroideremia: Initial fi ndings from a phase 1/2 clinical trial by MacLaren, R, MacLaren, R, MacLaren, R, Groppe, M, Groppe, M, Groppe, M, Barnard, A, Cottriall, C, Tolmachova, T, Seymour, L, Reed Clark, K, During, M, Cremers, F, Black, G, Lotery, A, Downes, S, Downes, S, Webster, A, Webster, A, Seabra, M, Seabra, M